These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30099888)

  • 1. Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem.
    Bartlett JW; Renner E; Mouland E; Barnes GD; Kuo L; Ha NB
    Ann Pharmacother; 2019 Jan; 53(1):21-27. PubMed ID: 30099888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function.
    Pham P; Schmidt S; Lesko L; Lip GYH; Brown JD
    JAMA Netw Open; 2020 Apr; 3(4):e203593. PubMed ID: 32329770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
    Washam JB; Hellkamp AS; Lokhnygina Y; Piccini JP; Berkowitz SD; Nessel CC; Becker RC; Breithardt G; Fox KAA; Halperin JL; Hankey GJ; Mahaffey KW; Singer DE; Patel MR;
    Am J Cardiol; 2017 Aug; 120(4):588-594. PubMed ID: 28645473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Hsueh YH; Izem R; Southworth MR; Wei Y; Liao J; Goulding MR; Mott K; Chillarige Y; MaCurdy TE; Worrall C; Kelman JA
    JAMA Intern Med; 2016 Nov; 176(11):1662-1671. PubMed ID: 27695821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.
    Chang SH; Chou IJ; Yeh YH; Chiou MJ; Wen MS; Kuo CT; See LC; Kuo CF
    JAMA; 2017 Oct; 318(13):1250-1259. PubMed ID: 28973247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation.
    Sychev D; Mirzaev K; Cherniaeva M; Kulikova M; Bochkov P; Shevchenko R; Gorbatenkova S; Golovina O; Ostroumova O; Bahteeva D; Rytkin E
    Drug Metab Pers Ther; 2020 Sep; 35(3):. PubMed ID: 32975202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
    Laliberté F; Cloutier M; Nelson WW; Coleman CI; Pilon D; Olson WH; Damaraju CV; Schein JR; Lefebvre P
    Curr Med Res Opin; 2014 Jul; 30(7):1317-25. PubMed ID: 24650301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
    Tepper PG; Mardekian J; Masseria C; Phatak H; Kamble S; Abdulsattar Y; Petkun W; Lip GYH
    PLoS One; 2018; 13(11):e0205989. PubMed ID: 30383768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHA
    Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
    Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
    Myers SP; Dadashzadeh ER; Cheung J; Alarcon L; Kutcher M; Brown JB; Neal MD
    J Trauma Acute Care Surg; 2017 Mar; 82(3):542-549. PubMed ID: 28045742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke.
    Cerezo-Manchado JJ; Navarro-Almenzar B; Elvira-Ruiz G; García-Candel F; Flores-Blanco PJ; Caro-Martínez C; Manzano-Fernández S; García-Iniesta N; Sánchez-García J; Cabañas-Perianes V; Moraleda-Jiménez JM
    Future Cardiol; 2018 May; 14(3s):31-37. PubMed ID: 29848091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation with rivaroxaban in a hematology unit: clinical profile, events and discontinuation rates in real-life patients with nonvalvular atrial fibrillation.
    Gavín Sebastián O; Izuzquiza Fernández M; Martínez Fernández R; Palomera Bernal L
    Future Cardiol; 2018 May; 14(3s):25-30. PubMed ID: 29848092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.
    Farag M; Gorog DA
    Future Cardiol; 2015 Mar; 11(2):147-51. PubMed ID: 25760874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function
.
    Weir MR; Haskell L; Berger JS; Ashton V; Laliberté F; Crivera C; Brown K; Lefebvre P; Schein J
    Clin Nephrol; 2018 May; 89(5):314-329. PubMed ID: 29231162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain.
    Muñiz Lobato S; Tarrazo Tarrazo C; González Fernández E; Morán Alcalá M
    Future Cardiol; 2018 May; 14(3s):17-24. PubMed ID: 29848093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants.
    Baker CL; Dhamane AD; Rajpura J; Mardekian J; Dina O; Russ C; Rosenblatt L; Lingohr-Smith M; Lin J
    Clin Appl Thromb Hemost; 2019; 25():1076029619870249. PubMed ID: 31418293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.